We are live on
!
Find out more
SCM
Soleus Capital Management Portfolio holdings
AUM
$2.47B
1-Year Est. Return
115.63%
This Fund
S&P 500
This Quarter
Est. Return
-5.2%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$642M
AUM Growth
-$8.55M
(-1.3%)
Cap. Flow
+$84.4M
Cap. Flow
% of AUM
13.15%
Top 10 Holdings %
Top 10 Hldgs %
47.56%
Holding
90
New
25
Increased
18
Reduced
19
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
+$30M |
| 2 |
United Therapeutics
UTHR
|
+$20.1M |
| 3 |
FLXN
Flexion Therapeutics, Inc.
FLXN
|
+$13M |
| 4 |
EPIX
ESSA Pharma
EPIX
|
+$10M |
| 5 |
Organogenesis Holdings
ORGO
|
+$9.94M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$18.7M |
| 2 |
SkinHealth Systems
SKIN
|
+$16.1M |
| 3 |
BioAtla
BCAB
|
+$10.9M |
| 4 |
NovoCure
NVCR
|
+$10.8M |
| 5 |
ITMR
Itamar Medical Ltd. American Depository Shares
ITMR
|
+$7.74M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.89% |
| 2 | Financials | 1.01% |
| 3 | Consumer Staples | 0.82% |
| 4 | Real Estate | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Halozyme
HALO
$10.2B
| – | – |
-44,100
| Closed | -$2M |
|
77
MiMedx Group
MDXG
$609M
| – | – |
-322,160
| Closed | -$4.03M |
|
78
Insulet
PODD
$9.66B
| – | – |
-8,980
| Closed | -$2.46M |
|
|
RPTX
79
DELISTED
Repare Therapeutics
RPTX
| – | – |
-7,300
| Closed | -$228K |
|
80
Revolution Medicines
RVMD
$42.4B
| – | – |
-125,700
| Closed | -$3.99M |
|
81
ARS Pharmaceuticals
SPRY
$551M
| – | – |
-31,306
| Closed | -$967K |
|
82
Alpha Teknova
TKNO
$350M
| – | – |
-114,546
| Closed | -$2.72M |
|
|
NARI
83
DELISTED
Inari Medical, Inc. Common Stock
NARI
| – | – |
-6,150
| Closed | -$574K |
|
|
RNLX
84
DELISTED
Renalytix plc American Depositary Shares
RNLX
| – | – |
-47,300
| Closed | -$1.46M |
|
|
TCRR
85
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| – | – |
-47,537
| Closed | -$780K |
|
|
KDMN
86
DELISTED
Kadmon Holdings, Inc.
KDMN
| – | – |
-86,442
| Closed | -$335K |
|
|
MSON
87
DELISTED
Misonix Inc
MSON
| – | – |
-100,788
| Closed | -$2.23M |
|
|
CMAX
88
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| – | – |
-3,963
| Closed | -$1.53M |
|
Similar funds
TW
M
SG
FFA
GWM
Q
SIM
QT
Soleus Capital Management's Q3 2021 Portfolio in Review
As of Q3 2021, Soleus Capital Management held 90 positions worth $642M, down 1.3% from $650M the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Soleus Capital Management deployed $84.4M of net new capital in Q3 2021, opening 25 new positions and adding to 18 existing holdings. Its largest new stake was DICE Therapeutics, Inc. Common Stock: 879,903 shares worth $28.8M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier, followed by Financials and Consumer Staples.
On the sell side, the largest reduction was IVERIC bio, Inc. Common Stock, an estimated $18.7M trimmed.
- Soleus Capital Management's largest Q3 2021 buy was DICE Therapeutics, Inc. Common Stock: 879,903 shares worth $28.8M.
- Soleus Capital Management added most to ESSA Pharma in Q3 2021, an estimated $10M increase.
- Soleus Capital Management's biggest Q3 2021 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $18.7M.
- Soleus Capital Management fully exited MiMedx Group in Q3 2021, selling an estimated $4.03M.
- Soleus Capital Management's ten largest holdings make up 48% of its $642M portfolio in Q3 2021.
- Soleus Capital Management opened 25 new positions and closed 18 in Q3 2021.
- Soleus Capital Management's portfolio value fell 1.3% quarter-over-quarter to $642M.
Based on Soleus Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.